However, because they are not FDA-approved, there are risks and questions about their consistency and effectiveness that patients should be aware of before committing
The most common time to see side effects like these are when you initially start the medication or when you are increasing the dose
if 4% or more of body weight has not been lost, it is unlikely the patient will achieve and sustain clinically meaningful weight loss with continued treatment
Use of GLP-1 drugs is highest among adults who report being diagnosed with conditions these drugs are prescribed to treat, including those who have ever been told by a doctor that they have diabetes (57% ever used, including 45% currently using), heart disease (40% ever, 29% currently), and those that have been told by a doctor that they are overweight or obese in the past five years (34% ever, 23% currently)
it's a critical piece of knowledge for making empowered health decisions
Eiger Biopharmaceuticals), the serotonin receptor 3 antagonist ondansetron (3 mg/kg